|1.||Ueno, Ryuji: 10 articles (02/2015 - 11/2004)|
|2.||Rao, Satish S C: 8 articles (09/2012 - 08/2006)|
|3.||Ueno, R: 5 articles (03/2012 - 06/2007)|
|4.||Lacy, Brian E: 4 articles (04/2015 - 04/2007)|
|5.||Chey, William D: 4 articles (04/2015 - 08/2008)|
|6.||Johanson, J F: 4 articles (03/2012 - 06/2007)|
|7.||Johanson, John F: 4 articles (09/2011 - 01/2007)|
|8.||Camilleri, Michael: 4 articles (06/2011 - 05/2006)|
|9.||Blikslager, Anthony T: 3 articles (12/2015 - 02/2007)|
|10.||Schey, Ron: 3 articles (03/2015 - 06/2011)|
01/01/2006 - "Significantly greater improvements occurred with lubiprostone than placebo in the degree of straining, stool consistency and constipation severity (where reported) in both pivotal studies (p < 0.05 for all comparisons at all timepoints). "
01/01/2006 - "In two pivotal, randomised, double-blind, multicentre phase III studies in patients with chronic idiopathic constipation, the frequency of spontaneous bowel movements (SBMs) was significantly greater in patients receiving lubiprostone 24microg twice daily than in those receiving placebo at each weekly timepoint throughout both 4-week studies (p < 0.05). "
11/21/2014 - "Both lubiprostone and Senna improved constipation-related symptoms and QOL in opioid-induced constipation, with no significant between-group differences."
11/01/2014 - "Pairwise comparisons showed significantly greater overall improvement for abdominal discomfort (P=0.047), straining (P<0.001), constipation severity (P=0.007), and stool consistency (P<0.001) with lubiprostone compared with placebo. "
04/01/2010 - "Lubiprostone-treated patients reported significant improvements in stool consistency, straining, and constipation severity at all weeks, and in abdominal bloating at week 1. Patient assessments of treatment effectiveness were significantly greater with lubiprostone compared with placebo at all weeks (P < 0.0004). "
|2.||Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
01/01/2009 - "A multi-center study of patients with IBS-C found that 8 microg of lubiprostone twice-daily improved both global and individual symptoms of irritable bowel syndrome. "
06/01/2011 - "Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study."
02/01/2015 - "Long-term administration of lubiprostone significantly increased scores from the Short-Form health survey and irritable bowel syndrome quality-of-life questionnaire, compared with baseline. "
10/01/2011 - "Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome."
04/01/2008 - "Lubiprostone significantly improved gastrointestinal symptoms of irritable bowel syndrome with constipation at all doses. "
05/01/2015 - "Lubiprostone significantly improved symptoms of OIC and was well tolerated in patients with chronic noncancer pain."
04/01/2008 - "After 2 months, all lubiprostone groups showed significantly greater improvements in mean abdominal discomfort/pain scores (P < or = 0.039). "
04/01/2008 - "After 1 month, lubiprostone showed significantly greater improvements in mean abdominal discomfort/pain scores vs. placebo (P = 0.023). "
11/01/2014 - "Lubiprostone effectively relieved OIC and associated signs and symptoms and was well tolerated in patients with chronic noncancer pain (http://clinicaltrials.gov/ct2/show/NCT00595946)."
02/01/2016 - "PAMORA MNTX and naloxegol and the intestinal chloride channel-2 (ClC-2) activator lubiprostone represent additional possible therapeutic options for the management of OIC in patients with chronic noncancer pain."
|4.||Abdominal Pain (Pain, Abdominal)
10/01/2011 - "In clinical trials, lubiprostone reduced the severity of abdominal pain. "
10/01/2011 - "The primary aim was to determine whether lubiprostone raises the threshold for abdominal pain induced by intraluminal balloon distention. "
01/14/2013 - "Clinical vigilance for ischemic colitis is recommended for patients receiving lubiprostone who are presenting with abdominal pain and rectal bleeding."
06/01/2015 - "Phase III clinical trials have demonstrated the efficacy of lubiprostone and linaclotide relative to placebo for the short-term treatment of IBS-C and CIC, with improvements reported in stool frequency, perceived constipation severity, and abdominal pain and discomfort. "
05/01/2015 - "Adverse events (AEs) >5% were diarrhea, nausea, vomiting, and abdominal pain (lubiprostone: 11.3, 9.9, 4.2, and 7.1%, respectively; placebo, 3.8, 4.7, 5.2, and 0%, respectively). "
12/01/2015 - "Oral preventive or therapeutic administration of lubiprostone significantly reduced the severity of colitis and reduced intestinal permeability in both DSS and trinitrobenzene sulfonic acid-induced colitis. "
12/01/2015 - "This study suggests a central role for ClC-2 in restoration of barrier function and tight junction architecture in experimental murine colitis, which can be therapeutically targeted with lubiprostone."
12/01/2015 - "Alternatively, when lubiprostone was administered to ClC-2 mice, the protective effect against DSS colitis was limited. "
12/01/2015 - "Preventive treatment with lubiprostone induced significant recovery of the expression and distribution of selected sealing tight junction proteins in mice with DSS-induced colitis. "
12/01/2015 - "We administered lubiprostone to wild-type or ClC-2 mice with dextran sulfate sodium (DSS) or 2, 4, 5-trinitrobenzene sulfonic acid-induced colitis. "
|1.||Chloride Channels (Chloride Channel)
|6.||Opioid Analgesics (Opioids)
|7.||Polyethylene Glycols (Polyethylene Glycol)
|9.||Serotonin (5 Hydroxytryptamine)
|3.||Drug Therapy (Chemotherapy)
|5.||Nebulizers and Vaporizers (Inhaler)